“Strengthening the strategies that we've been executing” tops the to-do list at Procter & Gamble, says Jon Moeller in his first conference presentation as president and CEO.
Change At P&G Helm But Not In Course
In First Presentation As P&G CEO, Moeller Notes Strengthening Sustainability
Speaking at conferences or in P&G’s earnings briefings wasn’t part of previous CEO David Taylor’s strategy. But Jon Moeller has been a mainstay of P&G presentations for years and likely will continue the role.
More from Leadership
• By
A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.
• By
The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.
• By
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
More from HBW Insight
• By
Single-use packaging producers subject to Oregon state’s Extended Producer Responsibility law that didn’t meet the 31 March deadline to report their packaging materials are given a grace period to report until 30 April, says Circular Action Alliance, the organization carrying out the EPR program.
• By
Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.
• By
Jump in cough & cold sales at the end of the year helps Recordati post higher OTC revenues for 2024.